Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia

被引：9
作者：
Al-Riyami, Arwa Z. [1 ,2 ]
Hudoba, Monika [1 ,2 ]
Young, Sean [3 ]
Forrest, Donna [2 ,4 ]
机构：
[1] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] British Columbia Canc Agcy, Dept Pathol & Lab Med, Canc Genet Lab, Vancouver, BC V5Z 4E6, Canada
[4] Vancouver Gen Hosp, British Columbia Canc Agcy, Div Hematol, Leukemia BMT Program British Columbia, Vancouver, BC, Canada
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 08期
关键词：
IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; FUSION; FIP1L1-PDGFRA; KINASE; DISCOVERY; INHIBITOR; NILOTINIB; DISEASE; MUTANT;
D O I：
10.3109/10428194.2012.749469
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1788 / 1790
页数：3
相关论文
共 10 条
[1]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214
[2]   Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias [J].
Gotlib, J. ;
Cools, J. .
LEUKEMIA, 2008, 22 (11) :1999-2010
[3]   Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome [J].
Griffin, JH ;
Leung, J ;
Bruner, RJ ;
Caligiuri, MA ;
Briesewitz, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7830-7835
[4]   FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib [J].
Lierman, E. ;
Michaux, L. ;
Beullens, E. ;
Pierre, P. ;
Marynen, P. ;
Cools, J. ;
Vandenberghe, P. .
LEUKEMIA, 2009, 23 (05) :845-851
[5]   Sorafenib is a potent inhibitor of HP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant [J].
Lierman, Els ;
Folens, Cedric ;
Stover, Elizabeth H. ;
Mentens, Nicole ;
Van Miegroet, Helen ;
Scheers, Werner ;
Boogaerts, Marc ;
Vandenberghe, Peter ;
Marynen, Peter ;
Cools, Jan .
BLOOD, 2006, 108 (04) :1374-1376
[6]   Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation [J].
Metzgeroth, G. ;
Erben, P. ;
Martin, H. ;
Mousset, S. ;
Teichmann, M. ;
Walz, C. ;
Klippstein, T. ;
Hochhaus, A. ;
Cross, N. C. P. ;
Hofmann, W-K ;
Reiter, A. .
LEUKEMIA, 2012, 26 (01) :162-164
[7]   Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy [J].
Ohnishi, Hiroaki ;
Kandabashi, Koji ;
Maeda, Yoshiharu ;
Kawamura, Machiko ;
Watanabe, Takashi .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (05) :547-549
[8]   Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions [J].
Score, J. ;
Walz, C. ;
Jovanovic, J. V. ;
Jones, A. V. ;
Waghorn, K. ;
Hidalgo-Curtis, C. ;
Lin, F. ;
Grimwade, D. ;
Grand, F. ;
Reiter, A. ;
Cross, N. C. P. .
LEUKEMIA, 2009, 23 (02) :332-339
[9]   Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia [J].
von Bubnoff, N ;
Sandherr, M ;
Schlimok, G ;
Andreesen, R ;
Peschel, C ;
Duyster, J .
LEUKEMIA, 2005, 19 (02) :286-287
[10]   The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib) [J].
von Bubnoff, Nikolas ;
Gorantla, Sivahari Prasad ;
Thoene, Silvia ;
Peschel, Christian ;
Duyster, Justus .
BLOOD, 2006, 107 (12) :4970-4971
1